Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality

Circulation

Volumn 100, Issue 24, 1999, Pages 2400-2405

  Hong, Mun K ^a,b   Mehran, Roxana ^a   Dangas, George ^a   Mintz, Gary S ^a   Lansky, Alexandra J ^a   Pichard, Augusto D ^a   Kent, Kenneth M ^a   Satler, Lowell F ^a   Stone, Gregg W ^a   Leon, Martin B ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Angioplasty; Creatine kinase; Myocardial infarction; Stents

Indexed keywords

CREATINE KINASE MB;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME;

EID: 0032786887     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.24.2400     Document Type: Article

References (12)

1. Oh JK, Shub C, Ilstrup DM, Reeder GS. Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1985;109:1225-1231.
2. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cordiol. 1991;17:621-626.
3. Kugelmass AD, Cohen DJ, Moscucci M, Piana RN, Senerchia C, Kuntz RE, Baim DS. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748-754.
4. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol. 1995;25:1693-1699.
5. Adgey AA, Mathew TP, Harbinson MT. Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin Cardiol. 1999;22:257-265.
6. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097-1105.
7. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
8. Kong TQ Jr, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466.
9. Popma JJ, Leon MB. A lesion-specific approach to new device angioplasty. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia: Sauders; 1994;973-985.
10. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ, for the EPIC investigators. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol. 1997;80:985-988.
11. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation. 1996;94:3369-3375.
12. Sharma SK, Kini A, Kini S, Dangas G, Brown E, Marmur JD, Ambrose JA. Cardioprotective effect of β-blocker therapy in reducing CK-MB release after coronary intervention. J Am Coll Cardiol. 1999;33(suppl A):38A. Abstract.